標(biāo)題: Titlebook: Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances; F. M. Muggia Book 1989 Kluwer Academic Publishers 1989 ca [打印本頁] 作者: 極大 時間: 2025-3-21 17:14
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances影響因子(影響力)
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances影響因子(影響力)學(xué)科排名
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances網(wǎng)絡(luò)公開度
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances被引頻次
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances被引頻次學(xué)科排名
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances年度引用
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances年度引用學(xué)科排名
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances讀者反饋
書目名稱Cancer Chemotherapy: Concepts, Clinical Investigations and Therapeutic Advances讀者反饋學(xué)科排名
作者: 割讓 時間: 2025-3-21 21:41
978-1-4612-8981-4Kluwer Academic Publishers 1989作者: hauteur 時間: 2025-3-22 00:56
Cancer Treatment and Researchhttp://image.papertrans.cn/c/image/221078.jpg作者: 尊嚴(yán) 時間: 2025-3-22 05:24 作者: 不怕任性 時間: 2025-3-22 10:43 作者: Affiliation 時間: 2025-3-22 15:37 作者: Affiliation 時間: 2025-3-22 18:44 作者: 植物群 時間: 2025-3-23 01:07
https://doi.org/10.1007/b138636anism(s) by which alkylating agents kill human tumor cells has not been completely characterized and is therefore not fully understood. The lack of understanding arises in part from the vast diversity of agents, both mono-functional and bifunctional, that have antitumor activity and also from the nu作者: 敵手 時間: 2025-3-23 01:42
https://doi.org/10.1007/b138636liative agents in the treatment of certain malignancies in adults [1–3] and have been employed to a limited extent in children [4, 5]. They constitute some of the most extensively studied anticancer agents. However, the relevant mechanism(s) of action in human cancers in vivo achieved at pharmacolog作者: Exclaim 時間: 2025-3-23 09:34 作者: 使尷尬 時間: 2025-3-23 10:05
https://doi.org/10.1007/b138636duce long-term remission [1]. Resistance occurs either because some cells are resistant de novo to the agent or agents used, or because resistant clones develop under the selective pressure of exposure to the drug [2], There are a variety of possible mechanisms to account for the development of drug作者: 音樂戲劇 時間: 2025-3-23 15:13 作者: 露天歷史劇 時間: 2025-3-23 18:09
https://doi.org/10.1007/978-3-662-08964-4 molecules for the delivery of cytotoxic compounds to cancer lesions and related diseases of cellular proliferation. As reagents, monoclonal antibodies appear ideal since they are homogeneous in nature, recognize specific antigenic determinants, are relatively stable to conjugation methods, and are 作者: 他很靈活 時間: 2025-3-23 23:15
https://doi.org/10.1007/978-3-642-83650-3ain malignancies have been achieved [1–5], many are still without successful therapies. The clinical trial serves as a mechanism whereby new and previously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitum作者: defeatist 時間: 2025-3-24 03:25
K. P. Wong,B. Y. Khoo,T. M. C. Tan,K. H. Sitodality in the treatment of this disease remains controversial [1, 2]. The accepted “standard” therapies, surgery and radiation are, of course, directed at the primary disease. The rationale for this aggressive local therapy is that 85%–90% of all patients presenting with squamous cell cancer of the作者: 說明 時間: 2025-3-24 08:34
Neurotransmitter Actions and Interactionsnant tumors. In 1987, there were an estimated 45,400 new cases of bladder cancer diagnosed in the United States with a male-female ratio of 3:1 and an annual death rate of 10,600 [1]. Although the disease is localized at the time of initial diagnosis in 90% of patients, 40% -80% will subsequently de作者: Commentary 時間: 2025-3-24 11:23
Opioid Peptides: Peripheral Nervous Systemiginates elsewhere in the body. Depending upon the specific pathologic type of disease, 5%–35% of systemic (non-Hodgkin’s) lymphomas may disseminate into the CNS during the natural course of the disease [1–4].作者: 手術(shù)刀 時間: 2025-3-24 17:48 作者: 吃掉 時間: 2025-3-24 20:19
Nasopharyngeal cancer, undifferentiated type: The medical oncologist’s viewpointNasopharyngeal carcinoma (NPC) has been dealt with separately by head and neck specialists ever since the description of its particular histopathologic characteristics simultaneously, but separately, by Schmincke [1] and Regaud and Reverchon [2].作者: 不要不誠實 時間: 2025-3-25 01:00
https://doi.org/10.1007/978-3-642-83650-3ously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitumor activity and toxicologic and pharmacologic determinations [7]. The three phases and objectives of clinical drug development include:作者: Innovative 時間: 2025-3-25 06:38 作者: 虛假 時間: 2025-3-25 10:32
K. P. Wong,B. Y. Khoo,T. M. C. Tan,K. H. SitThe ability to kill local tumor within the esophagus is less in doubt with systemic treatment of chemotherapy than the impact on that therapy on the overall survival of patients with squamous cell carcinoma of the esophagus (SCCE).作者: Haphazard 時間: 2025-3-25 13:09
The role of chemotherapy in the treatment of squamous cell tumors of the esophagusThe ability to kill local tumor within the esophagus is less in doubt with systemic treatment of chemotherapy than the impact on that therapy on the overall survival of patients with squamous cell carcinoma of the esophagus (SCCE).作者: A精確的 時間: 2025-3-25 16:00
Laboratory aspects of multidrug resistances chapter to emphasize the genetic nature of the MDR phenomenon and to review the studies that bear upon this. At the same time, we speculate on the implications of this phenotype for clinical cancer chemotherapy.作者: exclusice 時間: 2025-3-25 21:30 作者: 直言不諱 時間: 2025-3-26 01:30
https://doi.org/10.1007/978-3-662-08964-4ular receptors or circulating blood components such as the Fc receptor and complement. Fragmentation of the molecule can simplify its structure without damaging the antigenic binding sites or carrier function.作者: Flawless 時間: 2025-3-26 06:46 作者: 一小塊 時間: 2025-3-26 09:07
Alkylating agents: Mechanisms and modulationanism(s) by which alkylating agents kill human tumor cells has not been completely characterized and is therefore not fully understood. The lack of understanding arises in part from the vast diversity of agents, both mono-functional and bifunctional, that have antitumor activity and also from the nu作者: 無彈性 時間: 2025-3-26 16:32
Reduced folates and fluoropyrimidine antitumor efficacyliative agents in the treatment of certain malignancies in adults [1–3] and have been employed to a limited extent in children [4, 5]. They constitute some of the most extensively studied anticancer agents. However, the relevant mechanism(s) of action in human cancers in vivo achieved at pharmacolog作者: Extemporize 時間: 2025-3-26 19:05 作者: 宴會 時間: 2025-3-26 22:09 作者: follicular-unit 時間: 2025-3-27 01:17
Current status of trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties action [3–6] and spectrum of activity [7–11] and toxicity [12, 13] in preclinical trials, phase I clinical trials were begun in 1984 to define the maximally tolerated doses with various drug administration schedules [14–23]. These preliminary studies and more recent phase II trials [24–31] have sho作者: 半身雕像 時間: 2025-3-27 05:20
Daunomycin and doxorubicin Lym-1—drug conjugates for the treatment of malignant lymphomas molecules for the delivery of cytotoxic compounds to cancer lesions and related diseases of cellular proliferation. As reagents, monoclonal antibodies appear ideal since they are homogeneous in nature, recognize specific antigenic determinants, are relatively stable to conjugation methods, and are 作者: dyspareunia 時間: 2025-3-27 11:36
Phase I trials: Role of the nurse investigatorain malignancies have been achieved [1–5], many are still without successful therapies. The clinical trial serves as a mechanism whereby new and previously existing treatment modalities are evaluated in humans [6]. Such trials proceed in an orderly process following preclinical evaluation of antitum作者: 半球 時間: 2025-3-27 17:04 作者: SLUMP 時間: 2025-3-27 20:41
Systemic chemotherapy of transitional cell carcinoma of the urotheliumnant tumors. In 1987, there were an estimated 45,400 new cases of bladder cancer diagnosed in the United States with a male-female ratio of 3:1 and an annual death rate of 10,600 [1]. Although the disease is localized at the time of initial diagnosis in 90% of patients, 40% -80% will subsequently de作者: 真繁榮 時間: 2025-3-28 01:34 作者: 遺產(chǎn) 時間: 2025-3-28 05:17
https://doi.org/10.1007/b138636 to review information that is considered common knowledge, but to discuss results that do not appear to agree with current dogma and also to introduce new ideas concerning the mechanism of action of alkylating agents with which the reader may not be familiar. In addition, the ability to modulate th作者: Radiculopathy 時間: 2025-3-28 07:37 作者: exhilaration 時間: 2025-3-28 10:56
https://doi.org/10.1007/b138636clinical importance and the possible ways in which it may be circumvented. Multidrug resistance describes a complex phenotype whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic compounds, and has been observed to occur frequently in mammalian cell lines and t作者: 愉快嗎 時間: 2025-3-28 17:30
https://doi.org/10.1007/978-3-662-08964-4 III trials are currently under way to further define the activity of trimetrexate in these diseases. This chapter summarizes the preclinical and clinical data from published and unpublished reports on this new agent.作者: pus840 時間: 2025-3-28 18:45 作者: Gyrate 時間: 2025-3-29 00:22 作者: Immunoglobulin 時間: 2025-3-29 03:48
Alkylating agents: Mechanisms and modulation to review information that is considered common knowledge, but to discuss results that do not appear to agree with current dogma and also to introduce new ideas concerning the mechanism of action of alkylating agents with which the reader may not be familiar. In addition, the ability to modulate th作者: BET 時間: 2025-3-29 09:38 作者: 發(fā)炎 時間: 2025-3-29 13:42
Multidrug resistance: Clinical findings and implicationsclinical importance and the possible ways in which it may be circumvented. Multidrug resistance describes a complex phenotype whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic compounds, and has been observed to occur frequently in mammalian cell lines and t
